Search
Zucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. … It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions.
Danazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalDanazol has been used in the treatment of endometriosis and some benign breast disorders. … A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.
Categories: Sex Hormones and Modulators of the Genital SystemOxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseFlorilglutamic acid F-18
go.drugbank.com/drugs/DB15041InvestigationalFlorilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.
Tarlatamab
go.drugbank.com/drugs/DB17256ApprovedInvestigational[L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed … [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific
Conivaptan
go.drugbank.com/drugs/DB00872ApprovedConivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). … Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Synonyms: 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilideProducts: Vaprisol Dextrose In Plastic ContainerMelatonin
go.drugbank.com/drugs/DB01065ApprovedInvestigationalNutraceuticalVet approvedMost of the actions of melatonin are mediated through the binding and activation of melatonin receptors. … of melatonin synthesis.
Categories: Compounds used in a research, industrial, or household settingSynonyms: 5-methoxy-N-acetyl tryptamine, 5-methoxy-N-acetyltryptamineMeplazumab
go.drugbank.com/drugs/DB16465InvestigationalMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigational[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Categories: combinations of tetracyclines, Antiinfectives for Treatment of AcneProducts: Nu-minocycline